Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,303 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.
Moses MA, Kim YS, Rivera-Marquez GM, Oshima N, Watson MJ, Beebe KE, Wells C, Lee S, Zuehlke AD, Shao H, Bingman WE 3rd, Kumar V, Malhotra SV, Weigel NL, Gestwicki JE, Trepel JB, Neckers LM. Moses MA, et al. Among authors: kim ys. Cancer Res. 2018 Jul 15;78(14):4022-4035. doi: 10.1158/0008-5472.CAN-17-3728. Epub 2018 May 15. Cancer Res. 2018. PMID: 29764864 Free PMC article.
1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.
Ferroni C, Pepe A, Kim YS, Lee S, Guerrini A, Parenti MD, Tesei A, Zamagni A, Cortesi M, Zaffaroni N, De Cesare M, Beretta GL, Trepel JB, Malhotra SV, Varchi G. Ferroni C, et al. Among authors: kim ys. J Med Chem. 2017 Apr 13;60(7):3082-3093. doi: 10.1021/acs.jmedchem.7b00105. Epub 2017 Mar 20. J Med Chem. 2017. PMID: 28272894 Free PMC article.
Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells.
De Leon JT, Iwai A, Feau C, Garcia Y, Balsiger HA, Storer CL, Suro RM, Garza KM, Lee S, Kim YS, Chen Y, Ning YM, Riggs DL, Fletterick RJ, Guy RK, Trepel JB, Neckers LM, Cox MB. De Leon JT, et al. Among authors: kim ys. Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):11878-83. doi: 10.1073/pnas.1105160108. Epub 2011 Jul 5. Proc Natl Acad Sci U S A. 2011. PMID: 21730179 Free PMC article.
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, Gutierrez M, Crandon S, Zein WM, Jain L, Mannargudi B, Figg WD, Houk BE, Shnaidman M, Brega N, Giaccone G. Rajan A, et al. Among authors: kim ys. Clin Cancer Res. 2011 Nov 1;17(21):6831-9. doi: 10.1158/1078-0432.CCR-11-0821. Epub 2011 Sep 9. Clin Cancer Res. 2011. PMID: 21908572 Free PMC article. Clinical Trial.
Histone deacetylase inhibitors in cancer therapy.
Lee MJ, Kim YS, Kummar S, Giaccone G, Trepel JB. Lee MJ, et al. Among authors: kim ys. Curr Opin Oncol. 2008 Nov;20(6):639-49. doi: 10.1097/CCO.0b013e3283127095. Curr Opin Oncol. 2008. PMID: 18841045 Free PMC article. Review.
Inhibition of tumor cell motility by the interferon-inducible GTPase MxA.
Mushinski JF, Nguyen P, Stevens LM, Khanna C, Lee S, Chung EJ, Lee MJ, Kim YS, Linehan WM, Horisberger MA, Trepel JB. Mushinski JF, et al. Among authors: kim ys. J Biol Chem. 2009 May 29;284(22):15206-14. doi: 10.1074/jbc.M806324200. Epub 2009 Mar 18. J Biol Chem. 2009. PMID: 19297326 Free PMC article.
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL. Ning YM, et al. Among authors: kim ys. J Clin Oncol. 2010 Apr 20;28(12):2070-6. doi: 10.1200/JCO.2009.25.4524. Epub 2010 Mar 22. J Clin Oncol. 2010. PMID: 20308663 Free PMC article. Clinical Trial.
12,303 results
You have reached the last available page of results. Please see the User Guide for more information.